Innate Pharma SA (Euronext Paris: FR0010331421 – IPH), the innate immunity company developing first-in-class drugs for cancer and inflammatory diseases, announces its second participation to...

A Phase I Study of an Anti-KIR Antibody in Combination With an Anti-PD1 Antibody in Patients With Advanced Solid Tumors Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH), the...

23 patients, median age 71, in first complete remission, received escalating doses of IPH2101 Conclusions support the rationale behind the recently announced multicentre, double-blind, Phase II trial...

Three-year cash horizon resulting from collaboration and licensing agreement with Bristol-Myers Squibb Significant advance of the IPH21 program with the regulatory authorization to start the first...

First randomized Phase II trial of the anti-KIR antibody IPH2102 Led by French Cooperative Groups in AML and sponsored by Innate Pharma Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 –...

Innate Pharma (Euronext Paris: FR0010331421 – IPH) announces that its Annual General Meeting (“AGM”) took place on June 28, 2012, in Marseilles, France. A number of 21,148,778 votes were expressed out...

Innate Pharma (Euronext Paris: FR0010331421 – IPH) will hold its Annual General Meeting of Shareholders (“AGM”) on June 28, 2012, at 9:30 am in its headquarters, 117 avenue de Luminy, F-13009...

Immunotherapy and innate immunity targets are at the heart of the search for long-term, high quality of life responses for patients Bristol-Myers Squibb France and Innate Pharma are pleased to...

Innate Pharma (the “Company” - Euronext Paris: FR0010331421 – IPH) announces revenue of 3.0 million euros for the first quarter of 2012, compared with 1.0 million euros for the same period in 2011...

Panel of internationally renowned speakers including Nobel Prize winners in Medicine 2011 and Philippe Kourilsky, professor at the Collège de France, as moderator; Dedicated website www.immunite-innee...